Patents by Inventor Peter Edward DEAK
Peter Edward DEAK has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11638763Abstract: Embodiments of the present disclosure provide a nanoparticle based platform, and nanoallergens for identifying, evaluating and studying allergen mimotopes as multiple copies of a single mimotope or various combinations on the same particle. The nanoparticle is extremely versatile and allows multivalent binding to IgEs specific to a variety of mimotopes, simulating allergen proteins. Nanoparticles can include various molecular ratios of components. For example, the nanoallergens can include about 0.1-40% mimotope-lipid conjugate and about 60-99.9% lipid. The mimotope-lipid conjugate includes a mimotope, a first linker, and lipid molecule. Nanoallergens can be used in in vitro and in vivo applications to identify a specific patient's sensitivity to a set of epitopes and predict a symptomatic clinical response, identify allergen epitopes through blind screening peptide sequences from allergen protein, and in a clinical application similar to a scratch test.Type: GrantFiled: December 18, 2020Date of Patent: May 2, 2023Assignee: University of Notre Dame du LacInventors: Zihni Basar Bilgicer, Peter Edward Deak, Tanyel Kiziltepe Bilgicer, Jared Francis Stefanick, Jonathan Darryl Ashley
-
Publication number: 20210138089Abstract: Embodiments of the present disclosure provide a nanoparticle based platform, and nanoallergens for identifying, evaluating and studying allergen mimotopes as multiple copies of a single mimotope or various combinations on the same particle. The nanoparticle is extremely versatile and allows multivalent binding to IgEs specific to a variety of mimotopes, simulating allergen proteins. Nanoparticles can include various molecular ratios of components. For example, the nanoallergens can include about 0.1-40% mimotope-lipid conjugate and about 60-99.9% lipid. The mimotope-lipid conjugate includes a mimotope, a first linker, and lipid molecule. Nanoallergens can be used in in vitro and in vivo applications to identify a specific patient's sensitivity to a set of epitopes and predict a symptomatic clinical response, identify allergen epitopes through blind screening peptide sequences from allergen protein, and in a clinical application similar to a scratch test.Type: ApplicationFiled: December 18, 2020Publication date: May 13, 2021Applicant: University of Notre Dame du LacInventors: Zihni Basar BILGICER, Peter Edward DEAK, Tanyel KIZILTEPE BILGICER, Jared Francis STEFANICK, Jonathan Darryl ASHLEY
-
Publication number: 20210115157Abstract: The invention provides a strategy for site specific covalent modification of antibodies using a specialized targeting covalent heterobivalent ligand (cHBL), and corresponding design for a covalent heterobivalent inhibitor (cHBI) that can be used to prevent Immunoglobulin E (IgE) mediated allergic reactions triggered by drug molecules, according to one embodiment. These molecules contain four important components: (1) an IgE antigen binding site (ABS) ligand that can be a mimotope for the allergen protein, a small molecule, or a peptidomimetic, (2) an appropriate linker, which can be any flexible or rigid chemical linker, providing spacing between the ABS binder and the other moieties, (3) a nucleotide binding site (NBS) ligand, and (4) a reactive moiety to form a covalent link with an amino acid side chain of target IgE antibodies.Type: ApplicationFiled: December 18, 2020Publication date: April 22, 2021Applicant: University of Notre Dame du LacInventors: Zihni Basar BILGICER, Peter Edward DEAK, Tanyel KIZILTEPE BILGICER, Michael William HANDLOGTEN, Jonathan Darryl ASHLEY
-
Patent number: 10947320Abstract: The invention provides a strategy for site specific covalent modification of antibodies using a specialized targeting covalent heterobivalent ligand (cHBL), and corresponding design for a covalent heterobivalent inhibitor (cHBI) that can be used to prevent Immunoglobulin E (IgE) mediated allergic reactions triggered by drug molecules, according to one embodiment. These molecules contain four important components: (1) an IgE antigen binding site (ABS) ligand that can be a mimotope for the allergen protein, a small molecule, or a peptidomimetic, (2) an appropriate linker, which can be any flexible or rigid chemical linker, providing spacing between the ABS binder and the other moieties, (3) a nucleotide binding site (NBS) ligand, and (4) a reactive moiety to form a covalent link with an amino acid side chain of target IgE antibodies.Type: GrantFiled: December 19, 2016Date of Patent: March 16, 2021Assignee: University of Notre Dame du LacInventors: Zihni Basar Bilgicer, Peter Edward Deak, Tanyel Kiziltepe Bilgicer, Michael William Handlogten, Jonathan Darryl Ashley
-
Patent number: 10874751Abstract: Embodiments of the present disclosure provide a nanoparticle based platform, and nanoallergens for identifying, evaluating and studying allergen mimotopes as multiple copies of a single mimotope or various combinations on the same particle. The nanoparticle is extremely versatile and allows multivalent binding to IgEs specific to a variety of mimotopes, simulating allergen proteins. Nanoparticles can include various molecular ratios of components. For example, the nanoallergens can include about 0.1-40% mimotope-lipid conjugate and about 60-99.9% lipid. The mimotope-lipid conjugate includes a mimotope, a first linker, and lipid molecule. Nanoallergens can be used in in vitro and in vivo applications to identify a specific patient's sensitivity to a set of epitopes and predict a symptomatic clinical response, identify allergen epitopes through blind screening peptide sequences from allergen protein, and in a clinical application similar to a scratch test.Type: GrantFiled: September 26, 2016Date of Patent: December 29, 2020Assignee: University of Notre Dame du LacInventors: Zihni Basar Bilgicer, Peter Edward Deak, Tanyel Kiziltepe Bilgicer, Jared Francis Stefanick, Jonathan Darryl Ashley
-
Publication number: 20190375857Abstract: The invention provides a strategy for site specific covalent modification of antibodies using a specialized targeting covalent heterobivalent ligand (cHBL), and corresponding design for a covalent heterobivalent inhibitor (cHBI) that can be used to prevent Immunoglobulin E (IgE) mediated allergic reactions triggered by drug molecules, according to one embodiment. These molecules contain four important components: (1) an IgE antigen binding site (ABS) ligand that can be a mimotope for the allergen protein, a small molecule, or a peptidomimetic, (2) an appropriate linker, which can be any flexible or rigid chemical linker, providing spacing between the ABS binder and the other moieties, (3) a nucleotide binding site (NBS) ligand, and (4) a reactive moiety to form a covalent link with an amino acid side chain of target IgE antibodies.Type: ApplicationFiled: December 19, 2016Publication date: December 12, 2019Applicant: University of Notre Dame du LacInventors: Zihni Basar BILGICER, Peter Edward DEAK, Tanyel KIZILTEPE BILGICER, Michael William HANDLOGTEN, Jonathan Darryl ASHLEY